The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Journal Title: OncoReview - Year 2012, Vol 2, Issue 2
Abstract
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic arterial hypertension, which is a typical (“class effect”) vascular complication and a predictive factor of the anticancer efficiency. A biochemical and molecular aspect is associated with cardiomyocytes damage and endothelial dysfunction. Specific primary cardioprotective options are still unknown. It was shown the real risk of cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, in relation to the risk of cardiotoxicity of bevacizumab, the monoclonal antibody anti-VEGF.
Authors and Affiliations
Sebastian Szmit
Keywords
Related Articles
- EP ID EP53161
- DOI -
- Views 249
- Downloads 0
Radiotherapy in patients with cardiac implantable electronic devices – clinical experience
The number of patients with cardiac implantable electronic devices (CIEDs) constantly increases and due to growing incidence of cancer, many of them will require an anticancer treatment. At least a half of patients treat...
Heterogenność raka piersi - sprawozdanie z IMPAKT Breast Cancer Conference
W dniach 2–4 maja 2013 r. w Brukseli odbyła się 5. konferencja IMPAKT poświęcona tematyce badań podstawowych nad rakiem piersi. Najważniejszym zagadnieniem poruszanym podczas konferencji było zjawisko heterogenności raka...
Cardiac Biomarkers and Early Detection of Cardiotoxicity
Advanced pancreatic neuroendocrine tumor patient treated with everolimus – case report
The increasing incidence of gastroenteropancreatic neuroendocrine tumors is caused not exclusively by increasing number of new cases, but also by improved diagnostics. Proper diagnosis and evaluation of tumor differentia...
Nowa klasyfikacja NET
Zagadnienia związane z diagnostyką i kliniką nowotworów neuroendokrynnych przewodu pokarmowego dotyczą trzech kierunków działania. Pierwszym z nich jest zbieranie danych w ramach rejestrów gromadzących dane z różnych ośr...